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Abstract
Recently 2 groups have independently identified a mutation in the gene ‘vacuolar protein sorting 35 homolog’ (VPS35 c.1858GA;
p.Asp620Asn) as a possible cause of autosomal dominant Parkinson’s disease (PD). In order to assess the frequency of the reported mutation
and to search for other possible disease-causing variants in this gene, we sequenced all 17 exons of VPS35 in 96 familial PD cases, and exon
15 (in which the reported mutation is found) in an additional 64 familial PD cases, 175 young-onset PD cases, and 262 sporadic,
neuropathologically confirmed PD cases. We identified 1 individual with the p.Asp620Asn mutation and an autosomal dominant family
history of PD. Subsequent follow-up of the family confirmed an affected sibling and cousin who also carried the same mutation. No other
potentially disease-causing mutations were identified. We conclude that the VPS35 c.1858GA mutation is an uncommon cause of familial
Parkinson’s disease in our population.
© 2012 Elsevier Inc.
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e1. Introduction
Parkinson’s disease (PD) is a common neurodegenera-
tive disorder, affecting 2% of those over the age of 75 years
(Mayeux et al., 1995). Neuropathologically, it is character-
ized by a progressive loss of dopaminergic neurons of the
substantia nigra, associated with the formation of fibrillar
aggregates composed of -synuclein and other proteins
Lewy bodies and Lewy neurites) (Braak et al., 2003).
radykinesia, rest tremor, rigidity, and postural instability
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Open access under CC BY license.epresent the core clinical features (Poewe and Mahlknecht,
009).
Although generally considered a sporadic disease, Men-
elian forms of the disease are described and recent ge-
ome-wide association studies have shed considerable light
n the genetic contribution to sporadic disease (Interna-
ional Parkinson Disease Genomics Consortium, 2011a; In-
ernational Parkinson’s Disease Genomics Consortium (IP-
GC) and Wellcome Trust Case Control Consortium 2
WTCCC2], 2011b). Robust evidence exists for 2 genes
ausing autosomal dominant PD (SNCA, LRRK2) and 3
enes causing autosomal recessive, juvenile Parkinsonism
PINK1, Parkin, DJ-1) (Bonifati et al., 2003; Kitada et al.,
998; Paisán-Ruíz et al., 2004; Polymeropoulos, 1997; Valente
t al., 2004; Zimprich et al., 2004). Recently, using an exome
equencing-based approach, 2 independent groups have
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homolog (VPS35 c.1858GA; p.Asp620Asn) as the probable
cause of late-onset PD in a number of kindreds (Vilariño-Güell
et al., 2011; Zimprich et al., 2011). Pathogenicity is supported
by segregation, evolutionary conservation at that base, and
software predictions that the variant is likely to be damag-
ing. However, no other pathogenic mutations have been
identified with certainty in VPS35, and the c1858GA
mutation, thus far, has only been found in Caucasian
individuals. Additional evidence that VPS35 dysfunction
predisposes to familial Parkinson’s disease will come
from identification of other mutations which segregate
with Parkinson’s disease in families, and the observation
that VPS35 mutations occur in PD patients in other pop-
lations.
VPS35 is a highly-conserved component of the retro-
er, a heteropentameric complex that mediates retro-
rade transport of transmembrane cargo from endosomes
ack to the trans-Golgi network (Bonifacino and Rojas,
006; Seaman, 2005). In mammals, the full structure
omprises a sorting nexin dimer, composed of either
orting nexins (SNX) 1 or 2 and 5 or 6, as well as a
argo-recognition trimer, composed of VPS26, VPS29
nd VPS35 (Bonifacino and Hurley, 2008). It has been
ypothesized that the putative pathogenic mutation in
PS35 may act by disrupting recognition and binding to
ey cargo proteins (Zimprich et al., 2011). In terms of
eurodegenerative disease, recent work showing that
PS35 can associate directly with both soluble N-ethyl-
aleimide-sensitive factor attachment protein receptor
SNARE) proteins and the sortilin-related receptor
ORL1 is thus particularly interesting (Arighi et al.,
004; Bonifacino and Hurley, 2008; Nielsen et al., 2007).
. Methods
To estimate the frequency of VPS35 mutations and iden-
ify novel variants in our cohort of PD cases, we sequenced
ll 17 exons of VPS35 in 96 familial PD cases, and exon 15
in which the c.1858GA; p.Asp620Asn mutation is found)
n an additional 64 familial PD cases, 175 young-onset PD
ases, and 262 sporadic, neuropathologically confirmed PD
Table 1
Summary of variants found in VPS35
Variant Nucleotide change Amino acid change
Coding
Nonsynonymous c.1858GA p.Asp620Asn
Synonymous c.231TC p.Leu77Leu
c.1842TC p.Tyr615Tyr
c.1938CT p.His646His
Noncoding
UTR c.1-34GA
Intronic c.325AG
c.152442GC
c.1648-26GAKey: UTR, (untranslated region).ases (total number screened, 501). Neuropathologically
onfirmed cases were selected from the Queen Square and
Parkinson’s disease United Kingdom) brain bank. The
tudy was approved by the East Central London Research
thics Committee 1 and informed consent was obtained as
er its guidelines.
All living patients fulfilled criteria for clinical diag-
osis of PD at the time of the study with at least 2 of 3
ardinal signs of tremor, rigidity, and bradykinesia, as
ell as a positive response to levodopa therapy. Familial
ases were defined as those reporting 1 or more first
egree relatives with PD with a pedigree consistent with
utosomal dominant inheritance and negative testing for
nown mutations in SNCA and LRRK2. Young-onset PD
ases were defined as those who had developed their first
igns of the disease at age 45 or younger (mean age of
nset in young-onset PD was 37  6, range 14 – 45 with
male to female ratio of 1.63:1). A family history of PD
first or second degree relative) was noted in 31 young-
nset PD cases (17.7%). The neuropathological diagnosis
or brain bank cases was made by an experienced neuro-
athologist and based on accepted morphological criteria
Ince et al., 2008). This group included 166 males and 96
emales, with an average age at onset of 64  11 years
range, 29 – 85) and a family history recorded in 7.6% of
ases.
Genomic DNA was obtained from peripheral blood lym-
hocytes for all subjects using standard protocols. VPS35 ex-
ns 2–12 are located within a region that is duplicated 12
egabases (Mb) upstream. Primer pairs were designed specif-
cally to amplify these exons (available on request). Polymer-
se chain reaction (PCR) products were purified from unincor-
orated nucleotides using a Millipore PCR purification plate
Millipore, Co.Cork, Ireland). A total volume of 8 L of the
lean product and 10 pM of primer (forward or reverse) was
sed for sequencing. Amplicons were sequenced using the
ideoxynucleotide terminator chemistry and a 3730xl DNA
nalyzer (Applied Biosystems, Foster City, CA, USA). Se-
uences were analyzed using Sequencher software (Gene
odes Corporation, Ann Arbor, MI, USA, version 4.10.1).
umber (if known) Exon Number of cases
ently published 15 1
550462 4 1
el 15 1
8745 15 1
43928 1
el 1 1
66616 12 27 (2 homozygotes)
04492 14 58 (10 homozygotes)Rs n
Rec
rs11
Nov
rs16
rs37
Nov
rs49
rs23
t838.e3U.-M. Sheerin et al. / Neurobiology of Aging 33 (2012) 838.e1–838.e53. Results
Screening revealed a single case from our familial PD
cohort who harbored the previously described p.Asp620Asn
mutation. No other nonsynonymous variants were detected
in any other exon of any sample. The synonymous coding
and noncoding variants detected are summarized in Table 1.
A sibling and first cousin of the case in whom the
p.Asp620Asn mutation was identified, both also affected
with PD, were also found to carry the same mutation. The
family is of European ancestry, the pedigree (Fig. 1) is
consistent with autosomal dominant mode of inheritance
and revealed 9 further affected individuals across 3 gener-
ations, all of whom are deceased.
The index case (IV-7) noticed his first symptoms in 1993
at the age of 40, consisting of stiffness in the left arm on
waking followed, a few months later, by gradually worsen-
ing stiffness in the left leg. He was diagnosed as suffering
from PD in 1995. At that time, examination showed unilat-
eral bradykinesia and reduced arm swing. L-dopa was com-
menced with a good response, although he continued to
gradually worsen. He began to notice a mild intermittent
tremor of the left upper limb 13 years after his initial
symptoms, followed by the spread of the stiffness to his
right upper limb. Dyskinesias started after 9 years of L-dopa
therapy, but were not severe. He complains of difficulty
with balance, but has not had any falls. There is no history
of mood disturbance or other psychiatric features, including
visual hallucinations. Cognitively, he feels that his concen-
tration has deteriorated somewhat over the years, but he has
only recently retired from a demanding job. A Mini Mental
State Examination (MMSE) performed 18 years into the
disease revealed a score of 28/30. Olfactory testing was
undertaken 18 years into the disease, using the 40-item
University of Pennsylvania Smell Identification Test (UP-
SIT) (Doty et al., 1984) and results were interpreted in
comparison with 55 control subjects (27 males and 28
females) and 46 PD patients (30 males and 16 females) who
Fig. 1. Pedigree of a family showing autosomal dominant inheritance of Par
known for all descendants of I-1 and I-2. The p.Asp620Asn mutation of V
he disease.had been previously tested for a study about olfaction in the
UK (Silveira-Moriyama et al., 2009). The patient correctly
identified 29/40 items of the UPSIT, scoring on the 37th
percentile of 55 controls aged between 55 and 65 from the
UK, and the 87th percentile of 46 PD subjects aged between
55 and 65 from the UK.
His sibling (IV-8) developed symptoms aged 52 years of
age and was formally diagnosed 2 years later. Initial symp-
toms included cramping in the left foot and tripping when
walking. Within 6 months she developed a unilateral leg
tremor. Further symptoms included micrographia, and
freezing. Dopamine agonists were tried initially but within
3 years she required L-dopa. She has not developed any
dyskinesias. She does not report any cognitive symptoms
and a Mini Mental State Examination was 30/30. Olfactory
testing was undertaken 11 years into the disease as de-
scribed above with the patient also identifying 29/40 items
of the UPSIT. Individual IV-5 presented with a stiffness and
rigidity of the left leg at the age, followed by walking
difficulties, bradykinesia, loss of postural reflexes and mi-
crographia aged 47. There was no rest tremor. He was
diagnosed shortly afterward. He responded well to L-dopa,
but developed dyskinesias after 10 to 15 years of treatment
and has now had a deep brain stimulator implanted to good
effect. There have been no hallucinations or psychiatric
complications. The clinical history for individual IV-6 was
provided by her brother. She developed PD at the age of 41
with noticeable tremor and generalized bradykinesia and
rigidity. She responded well to L-dopa, developing only
mild dyskinesias after a reasonable period of treatment. She
underwent a pallidotomy at around 60 years of age and died
at age 66 as a consequence of a nosocomial infection after
a hip replacement operation.
Limited information is available for other affected family
members. Individual II-1 presented with akinetic-rigid par-
kinsonism in her late fourth decade, family members noted
that she never developed tremor, but suffered with depres-
s disease (PD). Age of onset (O:) and age at death (D:) are indicated where
as confirmed by Sanger sequencing in the 3 living individuals affected bykinson’
PS35 w
838.e4 U.-M. Sheerin et al. / Neurobiology of Aging 33 (2012) 838.e1–838.e5sion late in the disease course. She died aged 66 years.
Individuals II-3 and II-5 developed parkinsonism in their
seventh decade and died in their eighth decade. II-4 devel-
oped tremor-predominant Parkinson’s disease aged 35 years
and had a slowly progressive disease course, dying at the
age of 69. Individuals II-9 and II-10 are known to have been
affected with parkinsonism, but ages of onset are not
known. They died in their sixth and fourth decade respec-
tively. Individual III-7 developed parkinsonism at age 37.
Medical records and family members indicate left-sided
rigidity, bradykinesia, hypomimia, falls, and freezing.
Tremor was not recorded. Surgical interventions, including
pallidotomy (right then left) and thalamotomy, were per-
formed before L-dopa was commenced. No dyskinesias
developed despite 10 years of treatment and she died at age
62. Individual III-9 developed parkinsonism aged 47 years
presenting with a unilateral rest tremor. Family members
report early severe muscular spasms, difficulty walking, and
falls. Later in the disease, she developed depression and
cognitive impairment. She died aged 57 years.
4. Discussion
Recently, using exome sequencing, 2 groups have inde-
pendently identified a single c.1858GA mutation in
VPS35 as the probable cause of Parkinson’s disease in
several kindreds. Therefore, in this study, we screened our
own Parkinson’s population for variants in this gene, both in
order to estimate the frequency of the published mutations
and in order to search for novel mutations that may be
disease-causing. We included PD patients with a positive
family history, as well as those with early onset and late-
onset sporadic disease in order to maximize our chances of
identifying mutations.
We identified 1 individual with the published putative
disease-causing mutation (c.1858GA; p.Asp620Asn).
This individual had a family history that was consistent with
highly penetrant, autosomal dominant Parkinson’s disease.
Based on clinical examination, notes and family reports, the
disease in this family appears clinically similar to idiopathic
PD. Onset was generally unilateral, with slow progression
and variable tremor. Cognitive or psychiatric features are
not prominent. Response to L-dopa was generally good and
was not associated with early or unusually severe dyskine-
sias. The 2 patients in which olfaction was tested here show
mild to moderate olfactory dysfunction when compared
with controls in the UK, but still performed better than the
vast majority of PD patients. Olfaction has been demon-
strated to be unimpaired in homozygous and compound
heterozygous carriers of Parkin mutations (Alcalay et al.,
2011; Khan et al., 2004) but impaired in LRRK2 parkinso-
nian carriers (Healy et al., 2008; Saunders-Pullman et al.,
2011; Silveira-Moriyama et al., 2008, 2010), although not to
the same extent as in sporadic PD. The most notable feature
of our kindred is the relatively early age at onset. Sixindividuals developed PD in their third or fourth decades, of
which 4 were younger than the age of 45.
No other potentially disease-causing mutations were
found in exon 15 (597 cases screened) or in any other
exon (96 cases screened). It would seem reasonable to
conclude, therefore, that the recently published VPS35
c.1858GA mutation, is not a common cause of PD, in
our population.
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